Description: Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Home Page: www.cipla.com
Cipla House
Mumbai,
400013
India
Phone:
91 22 2482 6000
Officers
| Name | Title |
|---|---|
| Mr. Umang Vohra B.E., M.B.A. | MD, Global CEO & Executive Director |
| Dr. Raju Sunil Mistry M.A., Ph.D. | President & Global Chief People Officer |
| Mr. Pradeep Bhadauria | President & Global Chief Scientific Officer |
| Mr. Ashish Adukia | Global Chief Financial Officer |
| Mr. Dinesh Ramniranjan Jain | Senior VP & Head of Corporate Finance |
| Ms. Sneha Hiranandani B Com | Chief Information Officer |
| Ms. Diksha Maheshwari | Head of Investor Relations |
| Mr. Rajendra Kumar Chopra | Compliance Officer & Company Secretary |
| Ms. Heena Kanal | Senior Vice-President of Corporate Communications |
| Dr. Jaideep A. Gogtay M.D., Ph.D. | Global Chief Medical Officer |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 19.0114 |
|---|---|
| Trailing PE: | 26.6679 |
| Price-to-Book MRQ: | 4.2069 |
| Price-to-Sales TTM: | 4.5348 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 27764 |